In TME, we detected a higher level of IL-12 and IFN-γ (enhancing anti-tumor immunity) and lower level of TGF-β1 and IL-10 (suppressing anti-tumor immunity) in both treated groups. The gene discussed is TGFB1; the disease is neoplasm.